Michael Nagel, Chief Executive Officer of Raydiant Oximetry. “The FDA’s authorization to expand enrollment is an important milestone for the program. We look forward to continuing our collaboration with LSUHS as we build the clinical and technical foundation for an entirely new generation of fetal monitoring technologies.”